在格拉姆阴性败血症中,器官类型干预反应的药物保护学景观
Tirthankar Mohanty1, Christofer A Q Karlsson1, Yashuan Chao1
1Division of Infection Medicine, Department of Clinical Sciences, Lund, Lund University, SE-22184, Lund, Sweden.
Nature communications
|June 17, 2023
概括
败血症治疗的有效性因器官而异. 在败血症模型中,将美罗 (Mem) 与甲基prednisolone (Gcc) 结合起来,改善了脏炎症和代谢功能,突出了器官特定的治疗策略.
科学领域:
- 药物保护学 药物保护学 药物保护学
- 败血症病理生理学病理生理学
- 药物开发 药物开发
背景情况:
- 全球范围内,败血症是重症监护室死亡的主要原因.
- 了解败血症的分子事件对于有效的治疗和生物标志物开发至关重要.
- 目前针对败血症引起的器官功能障碍的治疗方法由于知识差距而不足.
研究的目的:
- 通过使用药物保护学来研究梅罗和甲基普雷迪尼索隆对败血症的时间依赖性影响.
- 为了确定特定器官的蛋白质组对败血症治疗的反应模式.
- 在小鼠败血症模型中评估联合疗法的潜在协同效应.
主要方法:
- 利用药物保护学来分析小鼠大肠杆菌败血症模型中的蛋白质组变化.
- 已服用β-乳糖类抗生素美罗 (Mem) 和/或葡萄糖皮质体甲基普雷迪尼索隆 (Gcc).
- 评估了依赖时间的治疗效果和器官类型蛋白质组反应.
主要成果:
- 根据器官蛋白型,确定了三种不同的蛋白质反应模式.
- 甲基prednisolone (Gcc) 增强了meropenem (Mem) 的积极作用,减少了炎和代谢功能障碍.
- 梅罗 (Mem) 引起了线粒体干扰,而甲基prednisolone (Gcc) 抵消了这种干扰.
结论:
- 败血症治疗的有效性取决于器官.
- 与美罗和甲基prednisolone的联合治疗显示出对治疗败血症诱导的器官功能障碍有希望.
- 为评估败血症疗法提出了一种定量,器官特定的策略.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...